Wire · opportunities
Voceryq Granted Accelerated Approval for Recurrent Respiratory Papillomatosis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
The FDA has granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy, to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP). This approval is based on phase 1/2 trial data showing 27% of patients achieved a complete response requiring no surgery in 12 months post-treatment.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
Voceryq’s approval signals a shift from surgery to immunotherapy in managing recurrent respiratory papillomatosis, opening new market opportunities for DNA-based immune therapies. You should explore partnerships or product pivots around targeted immunotherapies for respiratory conditions.
◆ Coverage
5 sources · 2 Nov 2026
◆ Related on Wire
◆ Topics